SYS-CON MEDIA Authors: Kevin Benedict, Gilad Parann-Nissany, Michael Bushong, Eric Brown

News Feed Item

Research and Markets: TNF-Alpha Signaling Pathway in Oncology Drug Pipeline Update 2014

Research and Markets (http://www.researchandmarkets.com/research/cm2s97/tnfalpha) has announced the addition of the "TNF-Alpha Signaling Pathway in Oncology Drug Pipeline Update 2014" report to their offering.

The TNF-alpha signaling pathway stimulates the MAPK signaling module and activates NFkB.

There are today 359 companies plus partners developing 531 TNF-alpha pathway targeting drugs in 1960 developmental projects in cancer. In addition, there are 7 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 250 drugs.

TNF-Alpha Signaling Pathway In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 247 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 243 out of the 245 studied drug targets so far have been recorded with somatic mutations.

The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 54 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.

Drug Pipeline Update at a Glance

Investigators

  • Includes more than 359 principal companies plus their collaborators. There is direct access from inside the application to web pages of all principal companies.

Drug name & Synonyms

  • Lists commercial, generic and code names for drugs.

Developmental stage

  • This Drug Pipeline Update contains 531 TNF-alpha pathway targeting drugs in development, which have a total of 1960 developmental projects in cancer. In addition there are suspended and ceased drugs.

Indications

  • Included TNF-alpha pathway targeting drugs are also in development for 224 other indications, where of 140 are different cancer indications.

Pipeline Breakdown According to Number of Drugs

  • Marketed # 39
  • Registered # 1
  • Pre-registration # 6
  • Phase III # 64
  • Phase II # 184
  • Phase I # 234
  • Preclinical # 280
  • No Data # 4
  • Suspended # 7
  • Ceased # 250

For more information visit http://www.researchandmarkets.com/research/cm2s97/tnfalpha.

More Stories By Business Wire

Copyright © 2009 Business Wire. All rights reserved. Republication or redistribution of Business Wire content is expressly prohibited without the prior written consent of Business Wire. Business Wire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.